A Greek Observational Study on Relapse Rate and Sustained Virological Response in Naive CHC [chronic hepatitis C] Patients, Treated With Pegylated Interferon Alpha-2b and Ribavirin in Daily Clinical Practice.

Trial Profile

A Greek Observational Study on Relapse Rate and Sustained Virological Response in Naive CHC [chronic hepatitis C] Patients, Treated With Pegylated Interferon Alpha-2b and Ribavirin in Daily Clinical Practice.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jan 2014

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Merck & Co; Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Oct 2011 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
    • 04 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top